Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
3
×
life sciences
national blog main
boston blog main
boston top stories
drugs
fda
san francisco blog main
san francisco top stories
accelerated approval
acute hepatic porphyria
alnylam pharmaceuticals
aminolevulinic acid
arena pharmaceuticals
biotech
boston
boulder/denver blog main
boulder/denver top stories
cancer
cannabidiol
cardiovascular disease
colorectal cancer
detroit blog main
detroit top stories
dravet syndrome
eisai
epidiolex
europe blog main
europe top stories
fen-phen
fenfluramine
givosiran
gw pharmaceuticals
indiana blog main
indiana top stories
lennox-gastaut syndrome
lorcaserin
lung cancer
national
national top stories
What
drug
market
3
×
medicine
3
×
data
fda
pharmaceuticals
ago
alnylam
approved
battle
cancer
cannabis
cleared
derivative
eisai
epilepsy
far
flags
form
gw
gw’s
higher
incidence
interference
lorcaserin
loss
marijuana
marketing
nasdaq
new
ok
patients
post
pulls
rare
risks
rna
rnai
second
seek
Language
unset
Current search:
market
×
medicine
×
" clinical trials "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
